After 2026-01-30, Bender Jeremy's DAWN filings point to a sequence worth tracking

Alex Rivera

Bender Jeremy's DAWN insider record stands at $5.2M cumulative sales (latest filing 2026-01-30); focus on sequence, transaction-code mix, and ownership trend over time.

Bender Jeremy continues to shape the insider narrative for DAWN. Cumulative sales are $5.2M, but the higher-value insight is in how filings cluster around 2026-01-30 and after.

Recent Form 4 Prints

DateCodeSharesPriceEst. Value
2026-01-30A237,000N/AN/A
2026-01-30A355,000$11.16$4.0M
2025-11-25G7,225N/AN/A
2025-11-25G7,225N/AN/A
2025-11-25G300,000N/AN/A
2025-11-25G300,000N/AN/A
2025-11-25G300,000N/AN/A
2025-11-25G300,000N/AN/A

Context for Day One Biopharmaceuticals, Inc.

In headline-sensitive environments, insider prints are easy to overread. A disciplined approach is to watch persistence outside expected liquidity windows.

Search-Based Context

Current search results for industry context

Bottom Line

Informative signal, not yet decisive; wait for follow-through data.

Explore all research